90%Confidence
0Views
FDASource
2026-03-30Date
Summary
New Life Pharma's Class II FDA recall for Semaglutide injection due to sterility assurance failures poses significant patient safety risks for this widely used diabetes/weight loss medication. This could lead to regulatory scrutiny, supply chain disruptions, and potential market opportunities for competitors like Novo Nordisk in the GLP-1 agonist space.
Actionable: Evaluate exposure to New Life Pharma and consider the potential for increased demand for established semaglutide manufacturers like Novo Nordisk.
AI Confidence: 90%
Data Points
firmNew Life Pharma LLC
classificationClass II
statusOngoing
distributionOH
productSemaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-001-06
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now